Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Health Benefits Independent of Weight Loss
NCT02520518Phase 2Terminated
- Start
- Aug 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in obesity, Overweight. Started Aug 2015; status: terminated.
02
Drugs
dapagliflozin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT02520518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520518.